Format

Send to

Choose Destination
Exp Neurol. 2016 Sep;283(Pt B):531-40. doi: 10.1016/j.expneurol.2016.02.023. Epub 2016 Mar 22.

The role of growth factors as a therapeutic approach to demyelinating disease.

Author information

1
Department of Neuroscience and Cell Biology, Rutgers Robert Wood Johnson Medical School, 683 Hoes Lane West, Piscataway, NJ 08854, USA. Electronic address: huangy4@rwjms.rutgers.edu.
2
Department of Neuroscience and Cell Biology, Rutgers Robert Wood Johnson Medical School, 683 Hoes Lane West, Piscataway, NJ 08854, USA. Electronic address: dreyfus@rwjms.rutgers.edu.

Abstract

A variety of growth factors are being explored as therapeutic agents relevant to the axonal and oligodendroglial deficits that occur as a result of demyelinating lesions such as are evident in Multiple Sclerosis (MS). This review focuses on five such proteins that are present in the lesion site and impact oligodendrocyte regeneration. It then presents approaches that are being exploited to manipulate the lesion environment affiliated with multiple neurodegenerative diseases and suggests that the utility of these approaches can extend to demyelination. Challenges are to further understand the roles of specific growth factors on a cellular and tissue level. Emerging technologies can then be employed to optimize the use of growth factors to ameliorate the deficits associated with demyelinating degenerative diseases.

KEYWORDS:

BDNF; CNTF; Cuprizone; Demyelinating disease; EAE; FGF; IGF-I; Lysolecithin; MS; PDGF; Therapeutic approaches to degenerative disease

PMID:
27016070
PMCID:
PMC5010931
DOI:
10.1016/j.expneurol.2016.02.023
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center